REBYOTA™ Prospective Registry

Launched by FERRING PHARMACEUTICALS · Apr 18, 2023

Keywords

ClinConnect Summary

The REBYOTA™ Prospective Registry is a clinical trial aimed at understanding how well a treatment called REBYOTA™ works to prevent the recurrence of Clostridium difficile infection (rCDI) in patients. This study collects information from patients who have received REBYOTA™ in their regular healthcare settings. The doctors will decide if the patient should receive REBYOTA™, and if so, the study will gather data about their health and any related events for six months after the treatment. This includes details about their medical history, symptoms, any hospital visits, and any side effects they might experience.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with rCDI by your doctor. You also need to have completed antibiotic treatment for your current infection and received a prescription for REBYOTA™. However, if you are already taking part in another clinical trial, you won’t be able to join this one. Overall, this study will help gather important information about how effective REBYOTA™ is in preventing rCDI, which could benefit future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed and dated informed consent form (ICF)
• • Age ≥ 18 years
• • Diagnosis of rCDI as determined by the treating physician
• • Completed antibiotic treatment for the presenting rCDI episode
• • Prescription for REBYOTA™ to prevent rCDI according to the approved indication
• Exclusion Criteria:
• • Currently enrolled in an interventional clinical trial